ReviewThe Eurasian journal of medicine2019
Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism.
Review in The Eurasian journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03988842 (Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis andFrontiers in neuroscience · 2026Article
- Management of High-Risk Pulmonary Thromboembolism Using Conventional Catheter Devices: A Case Report.The American journal of case reports · 2025Article
- Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report.Clinical case reports · 2025Article
- The dose of alteplase in massive pulmonary embolism: should it be individualized?Acute and critical care · 2025Article
- A Comprehensive Clinical Acumen Enhanced by Point-of-Care Ultrasonography in Managing Acute Life-Threatening Massive Pulmonary Thromboembolism in a Peripheral Setting: A Case Report.Annals of cardiac anaesthesia · 2025Article
- Venous Thromboembolism: Current Insights and Future Directions.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.Circulation · 2024Review
- Low-dose tenecteplase during cardiopulmonary resuscitation in massive pulmonary embolism.International journal of emergency medicine · 2024Article
- Percutaneous thrombolysis via cholecystostomy catheter to dissolve biliary clots causing obstructive jaundice.Journal of surgical case reports · 2024Article
- [Ultrasound-accelerated thrombolysis. Initial experience in patients with contraindications to systemic thrombolysis].Revista medica del Instituto Mexicano del Seguro Social · 2023Review
- Use of Autotransfusion following Percutaneous Thrombectomy for Cardiogenic Shock Due to Pulmonary Embolism in a Single Session-A Case Report.Diagnostics (Basel, Switzerland) · 2023Article
- Plant-Derived Compounds and Extracts as Modulators of Plasmin Activity-A Review.Molecules (Basel, Switzerland) · 2023Review
- Recurrent High-Risk Pulmonary Thromboembolism Treated with Repeated Thrombolytic Therapy Could be Helpful for Certain Patients: A Case Report and Review of the Literature.European journal of case reports in internal medicine · 2023Article
- Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical Application.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A Brief Review of Thrombolytics for Venous Interventions.Seminars in interventional radiology · 2022Review
- Safety and outcomes of thrombolytic therapy in patients with pulmonary embolism and thrombocytopenia: A systematic review.Qatar medical journal · 2022Article
- Surgical Treatment in a High-Risk Pulmonary Embolism: Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- A Case of Failure of EkoSonic™ Endovascular System in the Treatment of Submassive Pulmonary Embolism.Cureus · 2021Article
- Surgical pulmonary embolectomy in a multi-trauma patient: One-center experience in the resource-limited setting.SAGE open medical case reports · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombolytic treatment accelerates the dissolution of thrombus in acute pulmonary thromboembolism (PTE) and is potentially a lifesaving treatment. High-risk PTE is the clearest indication for this therapy, and its use in intermediate-risk cases is still controversial. A PTE response team may enable a rapid and effective determination of risk and treatment in these controversial clinical cases. Approved thrombolytic agents for the PTE treatment are streptokinase, urokinase, and alteplase. Currently, the most widely used agent is alteplase. It has a short infusion time (2 h) and a rapid effect. Newer, unapproved agents for the PTE treatment are tenecteplase and reteplase. The active resolution of thrombus via thrombolytic agents improves rapidly pulmonary perfusion, hemodynamic defect, gas exchange, and right ventricular dysfunction. However, it is important to determine appropriate candidates carefully, to prevent hemorrhage, which is the most important side effect of these drugs. Catheter-directed thrombolysis seems to be an alternative in patients not eligible for systemic thrombolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.